['polycythemia vera', 'essential thrombocythemia']
['rg7388', 'pegasys']

        Inclusion Criteria:

        (Patient should meet all the criteria)

          -  JAK2V617F-positive PV or JAK2V617F-positive ET (confirmed by WHO diagnostic criteria)

          -  High risk ET/PV [age >60; history of thrombosis] or low risk disease with symptoms
             [recurrent headaches, paresthesias, pruritus]

          -  Previously treated with at least one other agent [hydroxyurea, interferon, anagrelide]
             and determined to be either intolerant/resistant

             -≥18 years of age

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2

          -  Acceptable pre-study organ function during screening as defined as: Total bilirubin ≤
             1.5 times the upper limit of normal (ULN) unless due to Gilbert's disease or
             hemolysis, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5
             times ULN, Serum creatinine ≤ 1.5 x ULN

          -  Women of childbearing potential and males must agree to use adequate contraception
             (i.e., hormonal or barrier method of birth control; abstinence) prior to study entry
             and for the duration of study participation. Should a female subject become pregnant
             or suspect she is pregnant while participating in this study, she should inform the
             treating physician immediately

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Meets the criteria for post ET/PV MF as defined by the International Working
             Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

          -  Blast phase disease (>20% blasts in the marrow or peripheral blood)

          -  Acute thrombosis within 3 months of screening

          -  Uncontrolled intercurrent illness including, but not limited to hepatitis, human
             immunodeficiency virus (HIV) - positive subjects receiving combination antiretroviral
             therapy, ongoing or active infection, symptomatic congestive heart failure, unstable
             angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that
             would limit compliance with study requirements.
      